Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 9233
  • Home
  • Print this page
  • Email this page

   Table of Contents      
ARTICLES
Year : 1982  |  Volume : 30  |  Issue : 4  |  Page : 227-228

Timolol for glaucoma


Eye Department, Medical College, Amritsar, India

Correspondence Address:
Daljit Singh
Eye Deptt Medical College, Amritsar-143001
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 6131866

Rights and PermissionsRights and Permissions

How to cite this article:
Singh D. Timolol for glaucoma. Indian J Ophthalmol 1982;30:227-8

How to cite this URL:
Singh D. Timolol for glaucoma. Indian J Ophthalmol [serial online] 1982 [cited 2020 Feb 23];30:227-8. Available from: http://www.ijo.in/text.asp?1982/30/4/227/29434

Philips[1] discovered that beta-adrenegic blocking agents used in cardiology could reduce intraocular pressure. It took almost a decade to advance from the systemic use of beta-blocking agents to arrive at a local glau­coma treatment that did not cause any local or general side effect. The following is the list of 11 beta-blocking agents that have been studied by various workers for ocular hypo­tensive effects

Very potent drugs : Sotalol and Timolol Their action is stronger than pilocarpine.

Drugs with intermediate potency : Pindolol Oxprenolol, Bupranolol, Labetolol and Propra­nolol. Their action is comparable to pilocar­pine.

Less active drugs : Atenolol, Tiperanolol, Butidrine and Metoprolol.

Sotalol is 18 times inferior to Timolol, when used as local drops but equally effective in I/V experimental studies. That promotes Timolol to the highest place, as regards intra­ocular pressure reducing activity.

Mode of action

Timolol causes reduction in aqueous forma­tion. The action is different from the carbo­nic anhydrase inhibitors and therefore the two drugs can have additive effect. This is an important advance. Facility of outflow is not affected. Pupil size is not affected, therefore cases of narrow angle glaucoma, without a peripheral iridectomy are unsuitable for Timolol therapy.

Timolol is available in two strengths : 0.25%and 0.5%. The medicine needs to be instilled only once or twice a day. Only one drop is to be instilled. Every drop is costly and wastage should be avoided.

Duration of Action

The action of Timolol lasts much longer than 12 hours. Therefore twice a day is the maximum needed. Many patients need only one drop in 24 hours.


  Materials and methods Top


We have used Timolol in the 40 patients (22 Chronic simple glaucoma, Aphakic glau­coma : (2 patients had I.C.L.), 12 Secondary glaucoma following intraocular inflammation)

The choice of the patients for Timolol was made as follows

1. Where pilocarpine therapy had failed.

2. Where pilocarpine + diamox therapy had failed to control intraocular pressure.

3. Where conventional therapy with, with pilocarpine alone or pilocarpine -1- diamox was causing unwanted symptoms.


  Observations Top


Intraocular pressure in the patients varied from 26 and 58 mm Hg. Addition of Timolol achieved a fall of intraocular pressure ranging from 20 to 40 %.

1.0 P. was controlled in 31 out of 40 eyes. Addition of Timolol saved 7 eyes from surgery.

In 6 cases addition of Timolol made the inges­tion of diamox unnecessary. Follow up : was of 4 months to 20 months. Side effects noted were nil.


  Discussion Top


Advantages of Tirnolol over miotics are : ­no pupil constriction, no accommodation, no ocular discomfort, no retinal detachment, no shallowing of anterior chamber, no cata­ract formation and no iridocyclitis. The advantages over epinephrine : are no pupil dilatation, no maculopathy in aphakics, no conjunctival hyperaemia, no adrenochrome deposits and no ocular irritation. The advan­tages over carbonic anhydrase inhibitors are effective topically, no CNS effects, no GI effects, no kidney stones, no parasthesias, no acidosis and no weight loss. Thus Timo­lol has come out to be an important weapon in "therapeutic arsenal" of the ophthalmolo , gists in their fight againt glaucoma. This weapon is however not yet imported in India. We therefore, will have to depend upon bow . and arrow technology of pilocarpine and surgery for the time being.

The possibility of fighting glaucoma by Timolol, is especially welcome, since the mode of action is different from the medicines currently available. The action is also addi­tive with other medicines. Therefore it will be possible to treat a greater number of patients by medical means and save them from surgery and its natural complications.

 
  References Top

1.
Philips, C.I., Howitt, G. and Rowlands, DJ. 1967, Brit. J. Ophthalmol, 51 : 222.  Back to cited text no. 1
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Materials and me...
Observations
Discussion
References

 Article Access Statistics
    Viewed2066    
    Printed50    
    Emailed2    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal